

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

Re: D.I. 6

**INTERIM ORDER (I) ESTABLISHING NOTICE
AND OBJECTION PROCEDURES FOR TRANSFERS OF
EQUITY SECURITIES, (II) ESTABLISHING A RECORD DATE
FOR NOTICE AND SELL-DOWN PROCEDURES FOR TRADING IN CLAIMS
AGAINST THE DEBTOR'S ESTATE AND (III) SCHEDULING A FINAL HEARING**

Upon consideration of the *Motion For Entry of Interim and Final Orders (I) Establishing Notice and Objection Procedures for Transfers of Equity Securities and (II) Establishing a Record Date for Notice and Sell-Down Procedures for Trading in Claims Against the Debtor's Estate* (the "Motion")² pursuant to sections 105, 362 and 541 of the Bankruptcy Code and Rule 3001 of the Bankruptcy Rules, filed by the debtor in the above-captioned case (the "Debtor"); and the Court having jurisdiction to consider the Motion pursuant to 28 U.S.C. §§ 157 and 1334, and the *Amended Standing Order of Reference* from the United States District Court for the District of Delaware dated as of February 29, 2012; and venue of the Chapter 11 Case and the Motion in this district being proper pursuant to 28 U.S.C. §§ 1408 and 1409; and this matter being a core proceeding pursuant to 28 U.S.C. § 157(b); and proper and adequate notice of the Motion, the hearing thereon, and opportunity for objection having been given; and the relief requested in the Motion being in the best interests of the Debtor and its estate and creditors; and

¹ The last four digits of the Debtor's federal tax identification number are 8822. The Debtor's mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

² Capitalized terms not otherwise defined herein shall have the meanings given to them in the Motion.



the Court having heard evidence and statements of counsel regarding the Motion and having determined that the legal and factual bases set forth in the Motion and attested to in the First Day Declaration establish just cause for the relief granted herein; and the Court having determined that immediate relief is necessary to avoid irreparable harm; and after due deliberation and sufficient cause appearing therefor, **IT IS HEREBY ORDERED THAT:**

1. The Motion is GRANTED on an interim basis as set forth herein.
2. The Equity Transfer Procedures set forth herein are approved on an interim basis.
3. Effective as of the Petition Date and until further order of this Court to the contrary, any purchase, sale, trade or other transfer of Equity Securities in violation of the Equity Transfer Procedures set forth herein (including the notice requirements set forth in paragraph 4 below) shall be null and void *ab initio* as an act in violation of the automatic stay under section 362 of the Bankruptcy Code and shall confer no rights on the transferee.
4. The following notice and objection procedures for holding and transferring Equity Securities ("Equity Transfer Procedures") shall apply in the Debtor's Chapter 11 Case:

- i. Certain Defined Terms. For purposes of this interim order: (A) a "Substantial Equityholder" is any person or entity that beneficially owns at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Debtor or (ii) 9,899 shares of Series Z Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Debtor; (B) "beneficial ownership" of Equity Securities shall be determined in accordance with applicable rules under section 382 of the Internal Revenue Code of 1986 (as amended, the "IRC") and regulations promulgated thereunder and shall include (i) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all equity owned or acquired by its subsidiaries), (ii) ownership by such holder's family members and persons acting in concert with

such holder to make a coordinated acquisition of equity and (iii) ownership of options to acquire equity; (C) an “option” to acquire equity includes any contingent purchase, warrant, convertible debt, exchangeable shares, put, stock subject to risk of forfeiture, contract to acquire stock or similar interest, regardless of whether it is contingent or otherwise not currently exercisable; and (D) a “Transfer” means any transfer of Equity Securities to the extent described in paragraph 4(iii) below (Equity Security Acquisition Notice) and/or paragraph 4(iv) below (Equity Security Disposition Notice).

- ii. Notice of Substantial Equityholder Status. Any person or entity who currently is or becomes a Substantial Equityholder shall (a) file with the Court and (b) serve upon (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.) a notice of such status, in the form attached hereto as Exhibit 2 (a “Notice of Substantial Equityholder Status”), on or before the later of (A) 14 days after entry of the interim order or (B) 14 days after becoming a Substantial Equityholder.
- iii. Equity Security Acquisition Notice. At least 14 days prior to any transfer of Equity Securities (including any transfer of options to acquire equity or any exercise thereof) that would result in an increase in the amount of Equity Securities beneficially owned by a Substantial Equityholder or would result in a person or entity becoming a Substantial Equityholder, such Substantial Equityholder or potential Substantial Equityholder shall (a) file with the Court and (b) serve on the Debtor and proposed counsel to the Debtor (at the addresses set forth in paragraph 4(ii) above), advance written notice of the intended transfer of Equity Securities or worthless stock deduction, in the form attached hereto as Exhibit 3 (an “Equity Security Acquisition Notice”).
- iv. Equity Security Disposition Notice. Prior to any transfer of Equity Securities (including options) that would result in a decrease in the amount of Equity Securities beneficially owned by a Substantial Equityholder or would result in a person or entity ceasing to be a Substantial Equityholder, such Substantial Equityholder shall (a) file with the Court and (b) serve on the Debtor and proposed counsel to the Debtor (at the addresses set forth in paragraph 4(ii) above), advance written notice of the intended transfer of Equity Securities, in the form attached hereto as Exhibit 4 (an “Equity Security Disposition Notice”).

- v. Objection Procedures. The Debtor shall have 7 days after receipt of an Equity Security Acquisition Notice or Equity Security Disposition Notice (each, a "Transfer Notice") to file with the Court and serve on the party filing the Transfer Notice an objection to the proposed Transfer on the grounds that such Transfer may adversely affect the Debtor's ability to utilize its NOLs. If the Debtor files an objection, the proposed Transfer will not be effective unless and until approved by a final and nonappealable order of this Court. If the Debtor does not object within such 7-day period, the Transfer may proceed solely as set forth in the Transfer Notice. Further Transfers within the scope of this paragraph must comply with the Equity Transfer Procedures set forth in this paragraph 4.

5. Within five (5) business days after the entry of this interim order, the Debtor shall provide notice in substantially the form attached hereto as Exhibit 1 (the "Equity Transfer Procedures Notice") to: (a) the U.S. Trustee, (b) the United States Securities and Exchange Commission, (c) the Internal Revenue Service, (d) the Debtor's thirty (30) largest unsecured creditors as identified in its chapter 11 petition, (e) counsel to the DIP Administrative Agent, DIP Lenders, Prepetition Indenture Trustee and Secured Noteholders (as each is defined in the First Day Declaration), (f) all known holders of the outstanding Equity Securities, (g) any party that has requested notice pursuant to Bankruptcy Rule 2002, and (h) all parties entitled to notice pursuant to Local Rule 9013-1(m).

6. Upon receipt of such Equity Transfer Procedures Notice, any broker, bank, dealer or other agent or nominee of a beneficial holder of Equity Securities (each a "Nominee") will be required, within five (5) business days of receipt of such notice and on at least a quarterly basis thereafter, to send the Equity Transfer Procedures Notice to all beneficial holders of Equity Securities on whose behalf such Nominee holds Equity Securities. To the extent such beneficial holder is also a Nominee, such Nominee must, in turn, promptly provide the Equity Transfer Procedures Notice to any holder for whose account such holder holds Equity Securities, and so on down the chain of ownership. In addition, any person, entity, broker or

agent acting on behalf of any holder of Equity Securities who sells at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Debtor or (ii) 9,899 shares of Series Z Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Debtor to another person or entity must provide a copy of the Equity Transfer Procedures Notice to such purchaser or any broker or agent acting on such purchaser's behalf.

7. Claimholders and potential purchasers of Claims against the Debtor are hereby deemed notified that, if the Debtor ultimately seeks and the Court approves a Sell-Down Order, claimholders that acquire Claims after the date of this interim order (the "Record Date") in an amount that would entitle them to receive more than 4.5% of the stock of the Debtor may be subject to a required sell-down of any Claims acquired after the Record Date in accordance with the Sell-Down Procedures.

8. Within five (5) business days after the entry of this interim order, the Debtor shall provide notice in substantially the form attached hereto as **Exhibit 5** (the "Record Date Notice") to: (a) the U.S. Trustee, (b) the United States Securities and Exchange Commission, (c) the Internal Revenue Service, (d) the Debtor's thirty (30) largest unsecured creditors as identified in its chapter 11 petition, (e) counsel to the DIP Administrative Agent, DIP Lenders, Prepetition Indenture Trustee and Secured Noteholders (as each is defined in the First Day Declaration), (f) all known holders of the outstanding Equity Securities, and (g) any party that has requested notice pursuant to Bankruptcy Rule 2002.

9. Upon receipt of the Record Date Notice, any Nominee will be required, within five (5) days of receipt of the Record Date Notice, and on at least a quarterly basis thereafter, to send such Record Date Notice to all beneficial holders of the Debtor's Notes for

whose account such Nominee holds the Debtor's Notes. To the extent such beneficial holder is also a Nominee, such Nominee must, in turn, promptly provide the Record Date Notice to any holder for whose account such beneficial holder holds the Debtor's Notes, and so on down the chain of ownership.

10. Entry of this interim order shall in no way be deemed a determination of any kind that entry of a Sell-Down Order is necessary or warranted in this Chapter 11 Case and this Court's review of any request for the entry of a Sell-Down Order shall be without regard to entry of this interim order.

11. The entry of this interim order shall in no way prejudice the rights of any party to oppose the entry of a Sell-Down Order, on any grounds, and all parties' rights are expressly preserved hereby.

12. The notices substantially in the form attached hereto as Exhibit 1, Exhibit 2, Exhibit 3, Exhibit 4, and Exhibit 5 are approved.

13. The Debtor may waive in writing, and in its sole and absolute discretion, any and all restrictions, stays and notice procedures contained in this interim order.

14. The hearing to consider entry of an order granting the relief requested in the Motion on a final basis shall be held on April 11, 2018 at 10 a.m. (Eastern Time); and any objections to entry of such order shall be in writing, filed with the Court, and served upon (i) counsel to the Debtor, (ii) the United States Trustee, and (iii) counsel for any statutory committee appointed in this case so as to be received no later than 4:00 p.m. (Eastern Time) on April 3, 2018.

15. If no objections to the Motion are timely filed, served and received in accordance with the Motion and this interim order, the interim order shall be deemed a final

order upon expiration of the Objection Deadline without further notice or hearing, and the Motion shall be granted on a final and permanent basis.

16. If objections are timely filed and served as set forth herein, the Debtor shall, on or after the Objection Deadline, submit to the Court a final order substantially in the form of the final order attached to the Motion as **Exhibit B**.

17. The requirements set forth in this interim order are in addition to the requirements of Bankruptcy Rule 3001(e) and applicable law, and do not excuse compliance therewith.

18. Notice of the Motion as provided therein shall be deemed good and sufficient notice of the Motion.


19. This Order shall be immediately effective and enforceable upon its entry.

20. The Debtor is authorized to take all actions necessary to effectuate the relief granted pursuant to this interim order in accordance with the Motion.

21. The Court shall retain jurisdiction to hear and determine all matters arising from or related to this interim order.

22. Nothing in the Motion or this Order shall be deemed or construed as: (i) an admission as to the validity of any claim against the Debtor; (ii) a waiver of the Debtor's rights to dispute any claim on any grounds; (iii) a promise to pay any claim; or (iv) an implication or admission that any particular claim is a claim for payments authorized pursuant to the Motion.

Dated: March 13, 2018
Wilmington, Delaware



THE HONORABLE KEVIN GROSS
UNITED STATES BANKRUPTCY JUDGE

EXHIBIT 1 TO INTERIM ORDER

Equity Transfer Procedures Notice

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

NOTICE OF (I) EQUITY TRANSFER PROCEDURES AND (II) A FINAL HEARING
TO ALL PERSONS OR ENTITIES WITH EQUITY INTERESTS IN THE DEBTOR:

PLEASE TAKE NOTICE OF THE FOLLOWING:

1. On March 12, 2018 (the “Petition Date”), the above-captioned debtor (the “Debtor”) commenced this case under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware. You are receiving this notice because you have been identified as a potential equity holder in the Debtor. No bar date for filing proofs of interest has been established in the Debtor’s bankruptcy cases. For additional information regarding the Debtor’s chapter 11 case, please go to www.kccllc.net/orexigen.

2. On the Petition Date, the Debtor filed the Motion For Entry of Interim and Final Orders (I) Establishing Notice and Objection Procedures for Transfers of Equity Securities and (II) Establishing a Record Date for Notice and Sell-Down Procedures for Trading in Claims Against the Debtor’s Estate (the “Motion”).

3. On March __, 2018, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an interim order (the “Interim Order”), approving the procedures

¹ The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037

set forth below with respect to transfers of certain Equity Securities of the Debtor (the “Equity Transfer Procedures”) and setting the Record Date with respect to trading in claims against the Debtor, in order to assist the Debtor in preserving its net operating losses (“NOLs”). **Any purchase, sale, trade or other transfer of equity securities (including options) of the Debtor, in violation of the procedures set forth below shall be null and void *ab initio* as an act in violation of the automatic stay under section 362 of the Bankruptcy Code, and shall confer no rights on the transferee.**

4. The hearing to consider entry of an order granting the relief requested in the Motion on a final basis shall be held on _____, 2018 at _____ (Eastern Time); and any objections to entry of such order shall be in writing, filed with the Court, and served upon (i) counsel to the Debtor, (ii) the United States Trustee, and (iii) counsel for any statutory committee appointed in this case so as to be received no later than 4:00 p.m. (Eastern Time) on _____, 2018.

5. Objections to the Motion must be filed with the Court and served so as to be received by 4 p.m. (ET) on [____], 2018, on (a) the office of the United States Trustee for the District of Delaware and (b) (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.).

6. If no objections to the Motion are timely filed, served and received in accordance with the Interim Order, the Interim Order shall be deemed a Final Order without further notice or hearing, and the Motion shall be granted on a final and permanent basis.

7. Pursuant to the Interim Order, the following Equity Transfer Procedures shall apply to holding and transferring beneficial interests in Equity Securities:

- i. Certain Defined Terms. For purposes of the Interim Order and this Notice: (A) a “Substantial Equityholder” is any person or entity that beneficially owns at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Debtor or (ii) 9,899 shares of Series Z Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Debtor (“Equity Securities”); (B) “beneficial ownership” of Equity Securities shall be determined in accordance with applicable rules under section 382 of the Internal Revenue Code of 1986 (as amended, the “IRC”) and regulations promulgated thereunder and shall include (i) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all equity owned or acquired by its subsidiaries), (ii) ownership by such holder’s family members and persons acting in concert with such holder to make a coordinated acquisition of equity and (iii) ownership of options to acquire equity; (C) an “option” to acquire equity includes any contingent purchase, warrant, convertible debt, exchangeable shares, put, stock subject to risk of forfeiture, contract to acquire stock or similar interest, regardless of whether it is contingent or otherwise not currently exercisable; and (D) a “Transfer” means any transfer of Equity Securities to the extent described in paragraph 7(iii) below (Equity Security Acquisition Notice) and/or paragraph 7(iv) below (Equity Security Disposition Notice).
- ii. Notice of Substantial Equityholder Status. Any person or entity who currently is or becomes a Substantial Equityholder shall (a) file with the Court and (b) serve upon (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.), a notice of such status, in the form attached hereto as Exhibit 2 (a “Notice of Substantial Equityholder Status”), on or before the later of (A) 14 days after entry of the Interim Order or (B) 14 days after becoming a Substantial Equityholder.
- iii. Equity Security Acquisition Notice. At least 14 days prior to any transfer of Equity Securities (including any transfer of options to acquire equity or any exercise thereof) that would result in an increase in the amount of Equity Securities beneficially owned by a Substantial Equityholder or would result in a person or entity becoming a Substantial Equityholder, such Substantial

Equityholder or potential Substantial Equityholder shall (a) file with the Court and (b) serve on the Debtor and proposed counsel to the Debtor (at the addresses set forth in paragraph 7(ii) above), advance written notice of the intended transfer of Equity Securities, in the form attached hereto as Exhibit 3 (an “Equity Security Acquisition Notice”).

- iv. Equity Security Disposition Notice. Prior to any transfer of Equity Securities (including options) that would result in a decrease in the amount of Equity Securities beneficially owned by a Substantial Equityholder or would result in a person or entity ceasing to be a Substantial Equityholder, such Substantial Equityholder shall file with the Court and serve on the Debtor and proposed counsel to the Debtor (at the addresses set forth in paragraph 7(ii) above), advance written notice of the intended transfer of Equity Securities in the form attached hereto as Exhibit 4 (an “Equity Security Disposition Notice”).
- v. Objection Procedures. The Debtor shall have 7 days after receipt of an Equity Security Acquisition Notice or Equity Security Disposition Notice (each, a “Transfer Notice”) to file with the Court and serve on the party filing the Transfer Notice an objection to the proposed Transfer on the grounds that such Transfer may adversely affect the Debtor’s ability to utilize its NOLs. If the Debtor files an objection, the proposed Transfer will not be effective unless and until approved by a final and nonappealable order of this Court. If the Debtor does not object within such 7-day period, the Transfer may proceed solely as set forth in the Transfer Notice. Further Transfers within the scope of this paragraph must comply with the Equity Transfer Procedures set forth in this paragraph 7.
- vi. Unauthorized Transfers of Equity Securities. Effective as of the Petition Date and until further order of this Court to the contrary, any acquisition or disposition of Equity Securities (including options) in violation of the Equity Transfer Procedures shall be null and void ab initio as an act in violation of the automatic stay under section 362 of the Bankruptcy Code.

FAILURE TO FOLLOW THE PROCEDURES SET FORTH IN THIS NOTICE AND IN THE INTERIM ORDER SHALL CONSTITUTE A VIOLATION OF THE AUTOMATIC STAY UNDER SECTION 362 OF THE BANKRUPTCY CODE. ANY PROHIBITED PURCHASE, SALE, TRADE OR OTHER TRANSFER OF EQUITY SECURITIES (INCLUDING OPTIONS) IN OREXIGEN THERAPEUTICS INC. IN VIOLATION OF THE INTERIM ORDER WILL BE NULL AND VOID AB INITIO.

8. The Debtor may waive in writing, and in its sole and absolute discretion, any and all restrictions, stays and notice procedures contained in the Interim Order.

9. Complete copies of the Motion and the Interim Order are available via PACER via the Court's website at <https://ecf.deb.uscourts.gov> for a fee, or through the Debtor's Notice, Claims and Solicitation Agent, KCC, at www.kccllc.net/orexigen. If a hearing is held and a Final Order is entered, such Final Order will also be available as described in the preceding sentence.

10. The requirements set forth in this Notice are in addition to the requirements of Rule 3001(e) of the Federal Rules of Bankruptcy Procedure and applicable law, and do not excuse compliance therewith.

[remainder of page left intentionally blank]

March __, 2018
Wilmington, Delaware

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/

Robert J. Dehney (No. 3578)
Andrew R. Remming (No. 5120)
Jose F. Bibiloni (No. 6261)
1201 N. Market St., 16th Floor
P.O. Box 1347
Wilmington, DE 19899-1347
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
rdehney@mnat.com
aremming@mnat.com
jbibiloni@mnat.com

- and -

Christopher R. Donoho, III
Christopher R. Bryant
John D. Beck
HOGAN LOVELLS US LLP
875 Third Avenue
New York, NY 10022
Telephone: (212) 918-3000
Facsimile: (212) 918-3100
chris.donoho@hoganlovells.com
christopher.bryant@hoganlovells.com
john.beck@hoganlovells.com

Proposed Counsel for Debtor and Debtor in Possession

EXHIBIT 2 TO INTERIM ORDER

Notice of Substantial Equity-holder Status

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

NOTICE OF SUBSTANTIAL EQUITYHOLDER STATUS

PLEASE TAKE NOTICE OF THE FOLLOWING:

1. [Name of Equityholder] is/has become a Substantial Equityholder² with respect to the shares (the "Shares") of the above-captioned debtor (the "Debtor") or with respect to the Series Z Preferred stock (the "Preferred Stock"). Orexigen Therapeutics Inc. is the Debtor in Case No. 18-[], pending in the United States Bankruptcy Court for the District of Delaware (the "Court").

2. As of _____, 20__, [Name of Equityholder] beneficially owns _____ Shares of Debtor and/or options with respect to _____ Shares of Debtor.

¹ The last four digits of the Debtor's federal tax identification number are 8822. The Debtor's mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

² For purposes of this Notice: (A) a "Substantial Equityholder" is any person or entity that beneficially owns at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Orexigen Therapeutics, Inc. or (ii) 9,899 shares of Series A Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Orexigen Therapeutics, Inc.; (B) "beneficial ownership" of equity securities shall be determined in accordance with applicable rules under section 382 of the Internal Revenue Code of 1986 (as amended, the "IRC") and the regulations promulgated thereunder and shall include (i) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all equity owned or acquired by its subsidiaries), (ii) ownership by such holder's family members and persons acting in concert with such holder to make a coordinated acquisition of equity and (iii) ownership of options to acquire equity; and (C) an "option" to acquire equity includes any contingent purchase, warrant, convertible debt, exchangeable shares, put, stock subject to risk of forfeiture, contract to acquire stock or similar interest, regardless of whether it is contingent or otherwise not currently exercisable.

3. As of _____, 20__, **[Name of Equityholder]** beneficially owns _____ shares of the Preferred Stock of Debtor and/or options with respect to _____ shares of the Preferred Stock of Debtor.

4. The following table sets forth the date(s) on which **[Name of Equityholder]** acquired or otherwise became the beneficial owner of such Equity Securities:

Number of Shares of Debtor	Number of shares of Preferred Stock of Debtor	Date Acquired

(Attach additional page if necessary)

5. The last four digits of the taxpayer identification number of **[Name of Equityholder]** are _____.

6. Under penalty of perjury, **[Name of Equityholder]** hereby declares that it has examined this Notice and accompanying attachments (if any) and, to the best of its knowledge and belief, this Notice and any attachments that purport to be part of this Notice are true, correct and complete.

7. Pursuant to the **[Interim/Final]** Order establishing the Equity Transfer Procedures (as defined in the **[Interim/Final]** Order), this Notice is being (a) filed with the Court and (b) served upon (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.).

Respectfully submitted,

(Name of Equityholder)

By: _____

Name: _____

Title: _____

Address: _____

Telephone: _____

Facsimile: _____

Date: _____

EXHIBIT 3 TO INTERIM ORDER

Equity Security Acquisition Notice

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

EQUITY SECURITY ACQUISITION NOTICE

PLEASE TAKE NOTICE OF THE FOLLOWING:

1. [Name of Prospective Acquirer] hereby provides notice of its intention to purchase, acquire or otherwise accumulate (the “Proposed Transfer”) shares (the “Shares”) of Orexigen Therapeutics Inc. (the “Debtor”), or shares of Series A Preferred stock (the “Preferred Stock”) of Debtor, or to acquire or exercise an option with respect to such Shares or Preferred Stock. Orexigen Therapeutics is the Debtor in Case No. 18- [] pending in the United States Bankruptcy Court for the District of Delaware (the “Court”).

2. If applicable, on [Prior Date(s)], [Name of Prospective Acquirer] filed a Notice of Substantial Equityholder Status² with the Court and served copies thereof on the above-captioned debtor (collectively, the “Debtor”) and the Debtor’s counsel.

¹ The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

² For purposes of this Notice: (A) a “Substantial Equityholder” is any person or entity that beneficially owns at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Orexigen Therapeutics, Inc. or (ii) 9,899 shares of Series A Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Orexigen Therapeutics, Inc.; (B) “beneficial ownership” of equity securities shall be determined in accordance with applicable rules under section 382 of the Internal Revenue Code of 1986 (as amended, the “IRC”) and the regulations promulgated thereunder and shall include (i) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all equity owned or acquired by its subsidiaries), (ii) ownership by such holder’s family members and persons acting in concert with such

3. **[Name of Equityholder]** currently beneficially owns _____ Shares of Debtor and/or options with respect to _____ Shares of Debtor.

4. **[Name of Equityholder]** currently beneficially owns _____ shares of the Preferred Stock of Debtor and/or options with respect to _____ shares of the Preferred Stock of Debtor.

5. Pursuant to the Proposed Transfer, **[Name of Prospective Acquirer]** proposes, as applicable, to purchase, acquire or otherwise accumulate _____ Shares or an option (or to exercise such an option) with respect to _____ Shares. If the Proposed Transfer is permitted to occur, **[Name of Prospective Acquirer]** will beneficially own _____ Shares after the transfer becomes effective.

6. Pursuant to the Proposed Transfer, **[Name of Prospective Acquirer]** proposes, as applicable, to purchase, acquire or otherwise accumulate _____ shares of Preferred Stock or an option (or to exercise such an option) with respect to _____ shares of Preferred Stock. If the Proposed Transfer is permitted to occur, **[Name of Prospective Acquirer]** will beneficially own _____ shares of Preferred Stock after the transfer becomes effective.

7. The last four digits of the taxpayer identification number of **[Name of Prospective Acquirer]** are _____.

8. Under penalty of perjury, **[Name of Prospective Acquirer]** hereby declares that it has examined this Notice and accompanying attachments (if any) and, to the best

holder to make a coordinated acquisition of equity and (iii) ownership of options to acquire equity; and (C) an "option" to acquire equity includes any contingent purchase, warrant, convertible debt, exchangeable shares, put, stock subject to risk of forfeiture, contract to acquire stock or similar interest, regardless of whether it is contingent or otherwise not currently exercisable.

of its knowledge and belief, this Notice and any attachments which purport to be part of this Notice are true, correct and complete.

9. Pursuant to that certain **[Interim/Final]** Order establishing the Equity Transfer Procedures (as defined in the **[Interim/Final]** Order), this Notice is being (a) filed with the Court and (b) served upon (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.).

10. The Debtor has 7 calendar days after receipt of this Notice to object to the Proposed Transfer described herein. If the Debtor files an objection, such Proposed Transfer will not be effective unless approved by a final and nonappealable order of the Court. If the Debtor does not object within such 7-day period, then after expiration of such period the Proposed Transfer may proceed solely as set forth in this Notice.

11. The undersigned Prospective Acquirer understands that any further transactions that may result in **[Name of Prospective Acquirer]** purchasing, acquiring or otherwise accumulating Equity Securities (or an option with respect thereto) will each require an additional notice to be filed with the Court and served in the same manner as this Notice.

Respectfully submitted,

(Name of Prospective Acquirer)

By: _____

Name: _____

Title: _____

Address: _____

Telephone: _____

Facsimile: _____

Date: _____

EXHIBIT 4 TO INTERIM ORDER

Equity Security Disposition Notice

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

EQUITY SECURITY DISPOSITION NOTICE

PLEASE TAKE NOTICE OF THE FOLLOWING:

1. [Name of Prospective Seller], a Substantial Equityholder,² hereby provides notice of its intention to sell, trade or otherwise transfer (the “Proposed Transfer”) shares (the “Shares”) of Orexigen Therapeutics Inc. (“Debtor”), or options with respect thereto. Orexigen Therapeutics Inc. is the Debtor in Case No. 18-[] pending in the United States Bankruptcy Court for the District of Delaware (the “Court”).

2. If applicable, on [Prior Date(s)], [Name of Prospective Seller] filed a Notice of Substantial Equityholder Status with the Court and served copies thereof on the above-captioned debtor (collectively, the “Debtor”) and the Debtor’s counsel.

¹ The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

² For purposes of this Notice: (A) a “Substantial Equityholder” is any person or entity that beneficially owns at least (i) 849,916 shares (representing approximately 4.5% of the 18,887,033 issued and outstanding shares) of Orexigen Therapeutics, Inc. or (ii) 9,899 shares of Series A Preferred Stock (representing approximately 4.5% of the 219,994 issued and outstanding shares) of Orexigen Therapeutics, Inc.; (B) “beneficial ownership” of equity securities shall be determined in accordance with applicable rules under section 382 of the Internal Revenue Code of 1986 (as amended, the “IRC”) and the regulations promulgated thereunder and shall include (i) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all equity owned or acquired by its subsidiaries), (ii) ownership by such holder’s family members and persons acting in concert with such holder to make a coordinated acquisition of equity and (iii) ownership of options to acquire equity; and (C) an “option” to acquire equity includes any contingent purchase, warrant, convertible debt, exchangeable shares, put, stock subject to risk of forfeiture, contract to acquire stock or similar interest, regardless of whether it is contingent or otherwise not currently exercisable.

3. **[Name of Prospective Seller]** currently beneficially owns _____ Shares of Debtor and/or options with respect to _____ Shares of Debtor.

4. **[Name of Prospective Seller]** currently beneficially owns _____ shares of the Preferred Stock of Debtor and/or options with respect to _____ shares of the Preferred Stock of Debtor.

5. Pursuant to the Proposed Transfer, **[Name of Prospective Seller]** proposes to sell, trade or otherwise transfer _____ Shares or an option with respect to _____ Shares. If the Proposed Transfer is permitted to occur, **[Name of Prospective Seller]** will beneficially own _____ Shares after the transfer becomes effective.

6. Pursuant to the Proposed Transfer, **[Name of Prospective Seller]** proposes to sell, trade or otherwise transfer _____ shares of Preferred Stock or an option with respect to _____ shares of Preferred Stock. If the Proposed Transfer is permitted to occur, **[Name of Prospective Seller]** will beneficially own _____ shares of Preferred Stock after the transfer becomes effective.

7. The last four digits of the taxpayer identification number of **[Name of Prospective Seller]** are _____.

8. Under penalty of perjury, **[Name of Prospective Seller]** hereby declares that it has examined this Notice and accompanying attachments (if any) and, to the best of its knowledge and belief, this Notice and any attachments that purport to be part of this Notice are true, correct and complete.

9. Pursuant to that certain **[Interim/Final]** Order establishing the Equity Transfer Procedures (as defined in the **[Interim/Final]** Order), this Notice is being (a) filed with the Court and (b) served upon (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey

Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III. Esq. and John D. Beck, Esq.).

10. The Debtor has 7 calendar days after receipt of this Notice to object to the Proposed Transfer described herein. If the Debtor files an objection, such Proposed Transfer will not be effective unless approved by a final and nonappealable order of the Court. If the Debtor does not object within such 7-day period, then after expiration of such period the Proposed Transfer may proceed solely as set forth in this Notice.

11. The undersigned Prospective Seller understands that any further transactions that may result in **[Name of Prospective Seller]** selling, trading or otherwise transferring Equity Securities (or an option with respect thereto) will each require an additional notice to be filed with the Court and served in the same manner as this Notice.

Respectfully submitted,

(Name of Prospective Seller)

By: _____

Name: _____

Title: _____

Address: _____

Telephone: _____

Facsimile: _____

Date: _____

EXHIBIT 5 TO INTERIM ORDER

Record Date Notice

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

Orexigen Therapeutics, Inc.,

Debtor.¹

Chapter 11

Case No. 18-10518 (KG)

**NOTICE OF (I) RECORD DATE FOR
NOTICE AND SELL-DOWN PROCEDURES FOR TRADING IN
CLAIMS AGAINST THE DEBTOR'S ESTATE AND (II) A FINAL HEARING**

TO ALL PERSONS OR ENTITIES WITH CLAIMS AGAINST THE DEBTOR:

PLEASE TAKE NOTICE OF THE FOLLOWING:

1. On March 12, 2018 (the "Petition Date"), the above-captioned debtor (the "Debtor") commenced this case under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code").
2. On the Petition Date, the Debtor filed the Motion For Entry of Interim and Final Orders (I) Establishing Notice and Objection Procedures for Transfers of Equity Securities and (II) Establishing a Record Date for Notice and Sell-Down Procedures for Trading in Claims Against the Debtor's Estate (the "Motion").
3. On March __, 2018, the United States Bankruptcy Court for the District of Delaware (the "Court") entered an interim order (the "Interim Order") setting the Record Date with respect to trading in claims against the Debtor, in order to assist the Debtor in preserving its net operating losses ("NOLs").

¹ The last four digits of the Debtor's federal tax identification number are 8822. The Debtor's mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

4. Pursuant to the Interim Order, the Record Date is established as _____, 2018.

5. Pursuant to the Interim Order, claimholders and potential purchasers of claims against the Debtor ("Claims") are hereby notified that, if the Court ultimately approves a Sell-Down Order, claimholders that acquire Claims after the Record Date in an amount that would entitle them to receive more than 4.5% of the equity of the reorganized Debtor under a plan of reorganization may be subject to a required sell-down of any Claims purchased after the Record Date in accordance with the Sell-Down Procedures.

6. All persons or entities that acquired and hold Claims after the Record Date in an amount entitling such person or entity to receive more than 4.5% of the equity of the reorganized Debtor may be required to identify themselves to the Debtor after the Court's approval of the disclosure statement which identifies potential recoveries for creditors.

7. The hearing to consider entry of an order granting the relief requested in the Motion on a final basis shall be held on _____, 2018 at _____ (Eastern Time); and any objections to entry of such order shall be in writing, filed with the Court, and served upon (i) counsel to the Debtor, (ii) the United States Trustee, and (iii) counsel for any statutory committee appointed in these cases so as to be received no later than 4:00 p.m. (Eastern Time) on _____, 2018.

8. Objections to the Motion must be filed with the Court and served so as to be received by 4 p.m. (ET) on [____], 2018, on (a) the office of the United States Trustee for the District of Delaware and (b) (i) the Debtor, c/o Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037 (Attn: Tom Lynch), and (ii) proposed

counsel to the Debtor, Hogan Lovells US LLP, 875 3rd Ave, New York, NY 10022 (Attn: Christopher R. Donoho, III., Esq. and John D. Beck, Esq.).

9. If no objections to the Motion are timely filed, served and received in accordance with the Interim Order, the Interim Order shall be deemed a Final Order without further notice or hearing, and the Motion shall be granted on a final and permanent basis.

10. Complete copies of the Motion and the Interim Order are available via PACER via the Court's website at <https://ecf.deb.uscourts.gov> for a fee, or through the Debtor's Notice, Claims and Solicitation Agent, KCC, by accessing its website at www.kccllc.net/orexigen. If a hearing is held and a Final Order is entered, such Final Order will also be available as described in the preceding sentence.

11. The entry of the Interim and Final Orders shall in no way prejudice the rights of any party to oppose the entry of a Sell-Down Order, on any grounds, and all parties' rights are expressly preserved by the Interim and Final Orders.

12. The requirements set forth in this Notice are in addition to the requirements of Rule 3001(e) of the Federal Rules of Bankruptcy Procedure and applicable law, and do not excuse compliance therewith.

[remainder of page left intentionally blank]

March __, 2018
Wilmington, Delaware

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/

Robert J. Dehney (No. 3578)
Andrew R. Remming (No. 5120)
Jose F. Bibiloni (No. 6261)
1201 N. Market St., 16th Floor
P.O. Box 1347
Wilmington, DE 19899-1347
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
rdehney@mnat.com
aremming@mnat.com
jbibiloni@mnat.com

- and -

Christopher R. Donoho, III
Christopher R. Bryant
John D. Beck
HOGAN LOVELLS US LLP
875 Third Avenue
New York, NY 10022
Telephone: (212) 918-3000
Facsimile: (212) 918-3100
chris.donoho@hoganlovells.com
christopher.bryant@hoganlovells.com
john.beck@hoganlovells.com

Proposed Counsel for Debtor and Debtor in Possession